Psilocybin followed by accelerated iTBS for treatment-resistant depression
About this title
Read the official source — NCT06132178This study evaluates the safety and effectiveness of Psilocybin for people with depression.
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Psilocybin for people with depression.
Who could participate?
Listed age limits: 22 years to 65 years.
- Listed locations
- AustinSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- University of Texas at Austin
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Device, Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 22 Years to 65 Years
- Official registry ID
- NCT06132178
- Official title
Show the full official title
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder
Recruitment & locations
Austin
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Psilocybin for people with depression.
Who is behind this study?
The study sponsor is University of Texas at Austin, a university.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin and Low-dose psilocybin.
Who can participate?
Listed age limits: 22 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
